Cantel Medical Corp – Aggressive Growth – Zacks Rank Buy
Source: http://www.zacks.com/commentary/12780/Cantel+Medical+Corp+-+Aggressive+Growth+-+Zacks+Rank+BuyPosted on Wednesday, November 18th, 2009 | In Investing Lessons, Stocks to Watch
Cantel Medical Corp (CMN) posted yet another earnings surprise with a 65% increase in net income.
Company Description
Cantel makes medical products to prevent and control infections. The products are sold globally and range from water purification to disposable items like masks, wipes, and other products.
Net Income Up 65%
On Oct 9 the company reported fourth-quarter results that included a 65% jump in net income, to $4.3 million. Earnings per share came in at 26 cents, 4 cents higher than the Zacks Consensus Estimate and 10 cents higher than the same period last year.
A 4% rise in sales, to over $64 million, drove earnings higher. Cantel’s full-year earnings were up 79% to 94 cents, almost double last year’s 53 cents.
Fighting Swine Flu
Cantel sells a mask that is specially treated to fight infections, including seasonal flu and the H1N1 virus. The mask is treated with a special agent that breaks down the flu and other viruses.
Rising Estimates
Over the past few weeks, the average forecast for full-year 2010 rose 10 cents, to $1.03. Next year’s estimates are averaging $1.13, up 6 cents. This would show year-over-year growth of 10% and 9%, respectively.
The Chart
Below you can see that Cantel has a good recent history with earnings reports. After several misses a few years ago, the company has gone on to beat estimates in each of the past 6 quarters.
Last 5 posts by Zacks Market Commentaries
- Coventry Tops Zacks Consensus - Analyst Blog - February 9th, 2010
- W.R. Berkley Surpasses Estimates - Analyst Blog - February 9th, 2010
- Universal Forest Meets Loss Est - Analyst Blog - February 9th, 2010
- Biogen Beats & Guides Higher - Analyst Blog - February 9th, 2010
- Becton Recalls Catheters - Analyst Blog - February 9th, 2010
![]() About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |





